Shenzhen Chipscreen Biosciences Co., Ltd.

Shenzhen Chipscreen Biosciences Co., Ltd. has shown strong performance, with a notable increase today and a significant rise over the past week and month. Despite a challenging year, the company has achieved substantial returns over the last year, supported by impressive growth in operating cash flow and net profit.

Shenzhen Chipscreen Biosciences Co., Ltd. saw a notable stock decline today, contrasting with the broader market's performance. Despite recent challenges, the company has shown monthly growth and reported significant quarterly profit increases. However, concerns remain regarding its low return on capital and negative net worth.

Shenzhen Chipscreen Biosciences Co., Ltd. has seen a notable rise in stock performance, contrasting with the modest gains of the China Shanghai Composite. Despite facing long-term challenges, the company has demonstrated impressive growth in operating cash flow and net profit, indicating a potential turnaround in its financial health.

Shenzhen Chipscreen Biosciences Co., Ltd. saw a notable increase in stock performance on June 29, 2026, reaching an intraday high. The company reported substantial quarterly profit growth, while its year-to-date performance remains negative compared to the broader market. Its market capitalization stands at CNY 9,986 million.

Shenzhen Chipscreen Biosciences Co., Ltd. faced a significant stock decline today, contrasting with the broader market. Over the past week, the stock has dropped 10.7%, and year-to-date, it has decreased by 16.91%. Financial metrics reveal challenges, including low return on equity and negative net worth, despite recent profit increases.

Shenzhen Chipscreen Biosciences Co., Ltd. has shown resilience in its stock performance, achieving a notable increase on March 27, 2026. Despite a challenging month, the company has delivered strong year-to-date and annual returns, operating within the Pharmaceuticals & Biotechnology sector, with promising growth in cash flow and net profit.

Shenzhen Chipscreen Biosciences Co., Ltd. has shown notable performance, achieving an intraday high and a year-over-year return of 59.27%. Despite recent challenges, the company reported substantial increases in operating cash flow and pre-tax profit, while facing a negative return on equity. It operates in the pharmaceuticals and biotechnology sector.

Shenzhen Chipscreen Biosciences Co., Ltd. faced a decline in stock value amid broader market downturns, with notable weekly and monthly decreases. Despite recent challenges, the company has achieved significant annual growth and impressive increases in operating cash flow and pre-tax profit, reflecting its resilience in the Pharmaceuticals & Biotechnology sector.